Tag: Minerva 35

According to a 2018 review published in the journal 'Postępy Dermatologii i Alergologii', combination oral contraceptives (COCs) are a well-established treatment for androgen-related conditions. Minerva 35 is a medication that leverages this approach, using a potent combination of hormones to treat severe acne, hirsutism, and symptoms of polycystic ovary syndrome (PCOS) in women.

The name "Minerva" can refer to several distinct medications and even a medical device, leading to significant confusion among patients. In a pharmaceutical context, one common product is the hormonal contraceptive Minerva-35, while another is an antidiabetic tablet containing miglitol. The specific use of a drug under the "Minerva" name is entirely dependent on the product's active ingredients.

It's a common misconception that there is only one drug known as the 'Minerva pill', but the name can refer to two very different medications depending on the context. One is a combined hormonal contraceptive, while the other is an oral medication for managing type 2 diabetes.

Minerva 35, a hormonal medication containing cyproterone acetate and ethinylestradiol, is prescribed to women of reproductive age for treating androgen-dependent conditions. It is primarily used for moderate to severe acne and hirsutism, particularly when other treatments have failed. Due to its formulation, it also functions as an oral contraceptive, a factor clinicians must consider during prescribing.